June 2, 2015. Primary androgen deprivation therapy for localized prostate cancer increases diabetes risk by up to 60 per cent, particularly in men under 70 years of age, according to research published in the June issue of The Journal of Urology.
"As the benefits of primary androgen deprivation therapy for localized prostate cancer are controversial," the authors say, "and most prostate cancer survivors are of advanced age with comorbidities, it is important to determine if primary androgen deprivation therapy increases the risk of diabetes and to determine the susceptibility factors." ...continue reading Diabetes Risk For Men Treated With Primary Androgen Deprivation for Localized Prostate Cancer